0001317757-11-000020.txt : 20110628 0001317757-11-000020.hdr.sgml : 20110628 20110628162008 ACCESSION NUMBER: 0001317757-11-000020 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20110624 FILED AS OF DATE: 20110628 DATE AS OF CHANGE: 20110628 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: English Edward C CENTRAL INDEX KEY: 0001302600 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10865 FILM NUMBER: 11935991 MAIL ADDRESS: STREET 1: C/O PRAECIS PHARMACEUTICALS INCORPORATED STREET 2: 830 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMAG PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0000792977 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042742593 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 6174983300 MAIL ADDRESS: STREET 1: 100 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED MAGNETICS INC DATE OF NAME CHANGE: 19920703 3 1 primary_doc.xml PRIMARY DOCUMENT X0203 3 2011-06-24 0 0000792977 AMAG PHARMACEUTICALS INC. AMAG 0001302600 English Edward C C/O AMAG PHARMACEUTICALS, INC. 100 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 VP, Controller, Interim CFO Common Stock 88 D Stock Options 65.14 2017-05-22 Common Stock 7500 D Stock Options 59 2017-10-01 Common Stock 600 D Stock Options 47.08 2018-02-26 Common Stock 6000 D Stock Options 36.6 2018-07-01 Common Stock 1500 D Restricted Stock Units 2012-08-19 Common Stock 1000 D Stock Options 27 2019-03-04 Common Stock 7000 D Stock Options 38.39 2020-01-04 Common Stock 1750 D Stock Options 35.13 2020-03-02 Common Stock 4000 D Restricted Stock Units 2014-03-02 Common Stock 876 D Restricted Stock Units 2013-11-15 Common Stock 5000 D Stock Options 17.44 2020-12-17 Common Stock 2000 D These shares were acquired by the reporting person pursuant to the Company's 2006 Employee Stock Purchase Plan. The purchase price for the shares was $48.99, 85% of the closing price of the Company's common stock on November 30, 2007. Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Amended and Restated 2000 Stock Plan. This grant vested in four equal installments on May 22, 2008, May 22, 2009. May 22, 2010 and May 22, 2011. Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Amended and Restated 2000 Stock Plan. This grant vests in four equal installments. Installments one, two and three vested on October 1, 2008, October 1, 2009 and October 1, 2010, respectively. The fourth installment will vest on October 1, 2011. Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installments one, two and three vested on February 26, 2009, February 26, 2010 and February 26, 2011, respectively. The fourth installment will vest on February 26, 2012. Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installments one and two vested on July 1, 2009 and July 1, 2010. The third and fourth installments will vest on July 1, 2011 and July 1, 2012. Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests as follows: 50% on August 19, 2010, 25% on August 19, 2011 and the remaining 25% on August 19, 2012. Each restricted stock unit represents a contingent right to receive one share of common stock. Grant of stock option pursuant to the AMAG Pharmaceuticals Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installments one and two vested on March 4, 2010 and March 4, 2011. Installments three and four will vest on March 4, 2012 and March 4, 2013. Grant of stock option pursuant to the AMAG Pharmaceuticals Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installment one vested on January 4, 2011. Installments two, three and four will vest on January 4, 2012, January 4, 2013 and January 4, 2014, respectively. Grant of stock option pursuant to the AMAG Pharmaceuticals Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installment one vested on March 2, 2011. Installments two, three and four will vest on March 2, 2012, March 2, 2013 and March 2, 2014, respectively. Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments. Installment one vested on March 2, 2011. Installments two, three and four will vest on March 2, 2012, March 2, 2013 and March 2, 2014, respectively. Grant of restricted stock unit pursuant to the AMAG Pharmaceuticals Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests as follows: 50% on November 15, 2011, 25% on November 15, 2012 and the remaining 25% on November 15, 2013. Grant of stock option pursuant to the AMAG Pharmaceuticals, Inc. Second Amended and Restated 2007 Equity Incentive Plan. This grant vests in four equal installments on December 17, 2011, December 17, 2012, December 17, 2013 and December 17, 2014. Joseph L. Farmer, attorney-in-fact 2011-06-28 EX-99 2 powerofattorney.txt POWER OF ATTORNEY POWER OF ATTORNEY For Executing Forms 3, 4 and 5 Know all by these present,that the undersigned hereby constitutes and appoints each of Brian J.G. Pereira and Joseph Farmer, signing singly, his true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned,in the undersigneds capacity as an officer and/or director of AMAG Pharmaceuticals, Inc., or the Company, Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of any such Forms 3, 4 and 5 and the timely filing of such forms with the United States Securities and Exchange Commission and any other authority; and (3) take any other action of any type whatsoever in connection with the foregoing which,in the opinion of such attorney-in-fact may be of benefit to,in the best interest of,or legally required by,the undersigned,it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted,as fully to all intents and purposes as the undersigned might or could do if personally present,with full power of substitution or revocation hereby ratifying and confirming all that such attorney-in-fact, or his substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigneds responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended. This Power of Attorney replaces in their entirety any and all prior powers of attorney executed by the undersigned with respect to the subject matters set forth herein, including any powers of attorney previously filed with the Securities and Exchange Commission. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigneds holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 27th day of June 2011. Signed: /s/ Edward C. English Please Print: Edward C. Engish